Case Report

A Single Dose of Viperfav™ May Be Inadequate for Vipera ammodytes Snake Bite: A Case Report and Pharmacokinetic Evaluation

Tihana Kurtović 1,*,†, Miran Brvar 2,3,*,†, Damjan Grenc 2, Maja Lang Balija 1, Igor Križaj 4,5 and Beata Halassy 1

1 Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb, Rockefellerova 10, HR-10000 Zagreb, Croatia; tkurtovi@unizg.hr (T.K.); maja.langbalija@gmail.com (M.L.B.); beata.halassy@unizg.hr (B.H.)
2 Centre for Clinical Toxicology and Pharmacology, University Medical Centre Ljubljana, Zaloška cesta 7, 1000 Ljubljana, Slovenia; damjan.grenc@kclj.si
3 Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Zaloška cesta 4, 1000 Ljubljana, Slovenia
4 Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Jamova 39, 1000 Ljubljana, Slovenia; igor.krizaj@ijs.si
5 Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, 1000 Ljubljana, Slovenia
* Correspondence: miran.brvar@kclj.si; Tel.: +386-41-605-420
† These authors contribute equally to this work.

Academic Editor: Wayne Hodgson
Received: 30 June 2016; Accepted: 11 August 2016; Published: 19 August 2016

Abstract: Viperfav™ is a commercial F(ab′)2 antivenom prepared against European vipers venom. It is safe and effective for treating envenomation caused by Vipera aspis and Vipera berus. Therapeutic efficacy for treating Vipera ammodytes ammodytes (V. a. ammodytes) envenomening has not been yet described, although protective efficacy has been demonstrated in preclinical studies. We report on a 32-year-old man bitten by V. a. ammodytes who was treated with Viperfav™. Viperfav™ promptly reduced local extension and improved systemic pathological signs, but 24 h after the incident a recurrence of thrombocytopenia occurred despite a favorable pharmacokinetic profile with systemic clearance (1.64 (mL·h⁻¹)·kg⁻¹) and elimination half-life (97 h) among the highest ever reported. The recommended dose of Viperfav™ for V. aspis and V. berus bites may be inadequate for serious V. a. ammodytes envenomations. Following V. a. ammodytes bite, serial blood counts and coagulation profiles should be performed to help guide Viperfav™ treatment, along with supplemental administration as indicated.

Keywords: Vipera ammodytes ammodytes envenomation; Viperfav™ antivenom treatment; F(ab′)2 antivenom pharmacokinetics

1. Introduction

Vipera ammodytes ammodytes (V. a. ammodytes), the nose-horned viper, is the most common snake of medical importance in Slovenia [1]. Snakebite victims have recently been treated with Viperfav™ (Aventis Pasteur, MSD, Lyon, France), a formulation containing polyvalent equine F(ab′)2 fragments as an active principle against V. aspis, V. berus and V. a. ammodytes. Viperfav™ has been proven to be safe and effective for rapidly counteracting the pathophysiological manifestations that follow V. aspis and V. berus bites [2–7]. Pharmacokinetic and therapeutic efficacy against V. a. ammodytes venom-induced toxicity in human has not been described, although neutralisation efficacy has been proven preclinically.
We now report on a patient with *V. a. ammodytes* snakebite treated with Viperfav™ in whom the pharmacokinetics of antivenom immunoglobulin F(ab′)2 fragments was performed.

2. Case Description

2.1. Case Report

A 32-year-old man with no previous medical history was gathering mushrooms in a wooded area in central Slovenia when he was bitten in the proximal phalanx of the fourth finger of the left hand by an approximately 60 cm long snake with a “horn” on the snout and a dark brown dorsal zigzag pattern. The only naturally occurring medically important local snake is the nose-horned viper (*V. a. ammodytes*). Immediately after the bite he felt pain and noticed two puncture wounds on his finger. Within 10 min the left hand was entirely swollen. He called for help and walked to the nearest road. He was found sweating, faint and dizzy sitting by the road when the rescue team arrived 30 min later. The patient presented with oedema of the affected hand, extending up a third of the forearm toward the elbow. Upon arrival to the Emergency Department one hour after the viper bite, the patient was somnolent, bradycardic (55 beats/min) and normotensive (130/70 mmHg). He complained of intense pain at the envenomation site. Local oedema and erythema extended half way up the forearm. The remainder of his physical examination was unremarkable. Initial laboratory studies two hours after the bite revealed evidence of rhabdomyolysis (myoglobin 133 µg·L\(^{-1}\) (normal value: < 47 µg·L\(^{-1}\)), creatine kinase 11.6 µkat·L\(^{-1}\) (normal value: < 2.85 µkat·L\(^{-1}\)), coagulopathy with an extended prothrombin time (0.63) and profound thrombocytopenia (20 × 10\(^9\) L\(^{-1}\)). Pseudo-thrombocytopenia or analytical error due to possible in vitro formation of aggregates within a tube of the first blood sample was excluded by microscopic examination of blood smear and use of different buffers. Treatment was undertaken with 0.9% NaCl (100 mL·h\(^{-1}\)), after blood pressure dropped to 100/50 mmHg. Electrocardiogram (ECG) revealed sinus bradycardia at 45 beats/min. The patient had no neurological deficits. Four hours after the bite pain, oedema, erythema and lymphangitis extended to the upper arm and the envenomation was graded as grade 2b [4]. The patient was given 4 mL of Viperfav™ diluted in 250 mL of 0.9% NaCl within 60 min. This was followed by a second dose of 4 mL of Viperfav™ diluted in 250 mL of 0.9% NaCl. 15 min later ECG revealed sinus bradycardia of 30 beats/min with a junctional escape rhythm that persisted for one hour. The patient’s blood pressure remained 100/50 mmHg. Afterwards, the patient remained normotensive with a pulse between 55–70 beats/min. No additional treatment was required. Follow up studies six hours after the bite (immediately after the second antivenom infusion) revealed normalisation of platelet count (170 × 10\(^9\) L\(^{-1}\)) (Figure 1) and slight coagulopathy with prolongation of prothrombin time (0.58), while rhabdomyolysis (myoglobin 84 µg·L\(^{-1}\); creatine kinase 6.8 µkat·L\(^{-1}\)) improved. Fibrinogen level was normal (2.41 g·L\(^{-1}\); normal value: 1.8–3.5 g·L\(^{-1}\)). The spreading of oedema and erythema stopped and pain had decreased. 24 h after the bite a second drop in the platelet count occurred, with an eventual nadir of 40 × 10\(^9\) L\(^{-1}\) between 72 to 120 h post-snakebite (Figure 1). Petechiae and ecchymosis appeared on the affected limb. Microscopic examination of the blood smear showed giant platelets without schistocytes (platelet aggregates are not possible to observe in a blood smear). Direct and indirect anti-platelet antibody tests were negative, as were direct and indirect Coombs tests. All the other laboratory results, including white and red blood cells, glucose, electrolytes, urea, creatinine, myoglobin, hepatocellular enzyme levels, lactate, gas blood analysis, coagulation studies, fibrinogen and D-dimer remained within normal limits (data not shown). On the fifth day the platelet count increased, finally reaching normal values on the eighth day. The patient was ultimately discharged in good condition.
2.2. Detection of V. a. ammodytes Venom in Sera Samples

Serum V. a. ammodytes venom level two hours after the bite was 129 ng mL\(^{-1}\). Concentrations of V. a. ammodytes venom in subsequent sera samples are presented in Figure 1.

2.3. Pharmacokinetics of Antivenom Level Decrement

Pharmacokinetic parameters were derived from the serum antivenom concentration-time data fitted into a two-compartment model. The patient received two vials of Viperfav™ by intravenous infusion. A pre-treatment serum sample taken approximately 2 h after the snakebite contained no detectable antivenom, while those obtained after fabotherapy resembled a biexponential decline of concentration of F(ab')\(_2\) fragments according to the following mathematical equation (Figure 1):

when \(t \leq t_{\text{inf}}\),

\[
c(t) = A \times (1 - e^{-\alpha t}) + B \times (1 - e^{-\beta t})
\]

when \(t > t_{\text{inf}}\),

\[
c(t) = A \times (e^{-\alpha (t - t_{\text{inf}})} - e^{-\alpha t}) + B \times (e^{-\beta (t - t_{\text{inf}})} - e^{-\beta t})
\]

where \(c(t)\) is the antivenom concentration in the serum at any given time \(t\). Coefficient \(B\) is the \(y\)-intercept of the extrapolated line representing the elimination phase, while hybrid rate constant \(\beta\) is the slope. The \(y\)-intercept of the line was obtained by plotting the residuals—difference between the observed serum concentration-time data and the matching values on the extrapolated line versus their corresponding time values is equal to the coefficient \(A\) in the equation. The hybrid rate constant \(\alpha\) is the slope.

Compartmental analysis revealed that distribution \((t_{1/2\alpha})\) and elimination half-lives \((t_{1/2\beta})\) were 6.6 h and 97.6 h, respectively. The steady-state distribution volume \((V_{ss})\) corresponded to
213.7 mL·kg⁻¹. The mean residence time (MRT) was 130.3 h. The area under the antivenom concentration-time curve at t = ∞ (AUC∞) and the area under the first-order moment curve (AUMC) were determined as 6095 µg·h·mL⁻¹ and 793,893 µg·h²·mL⁻¹, respectively. The systemic clearance (CL) was 1.64 (mL·h⁻¹)·kg⁻¹ (Table 1).

Table 1. Pharmacokinetic parameters of Viperfay™ in the patient envenomed by V. a. ammodytes after i.v. administration.

| Pharmacokinetic Parameters | Values                       |
|-----------------------------|------------------------------|
| t1/2α                       | 6.56 h                       |
| t1/2β                       | 97.64 h                      |
| Vss                         | 213.7 mL·kg⁻¹                |
| MRT                         | 130.25 h                     |
| AUC∞                        | 6095 µg·h·mL⁻¹               |
| AUMC                        | 793,893 µg·h²·mL⁻¹           |
| CL                          | 1.64 (mL·h⁻¹)·kg⁻¹          |

Legend: t1/2α, distribution half-life; t1/2β, elimination half-life; Vss, steady-state volume of distribution; MRT, mean residence time; AUC∞, area under the curve at t = ∞; AUMC, area under the first-order moment curve; CL, systemic clearance.

3. Discussion

Insight into the metabolism of antivenom, from absorption to elimination, is necessary to optimise the management of snakebite envenomation. In an attempt to contribute a more complete understanding of antivenom clinical effectiveness and pharmacokinetic behaviour, we report for the first time on a patient bitten by V. a. ammodytes and treated with Viperfay™ in whom the pharmacokinetics of antivenom immunoglobulin F(ab’)₂ fragments was performed.

Viperfay™ was administered four hours after the V. a. ammodytes bite when local signs extended to the upper arm in the presence of severe thrombocytopenia and bradycardia with low blood pressure. At that time the envenomation was deemed to be at least grade 2b according to modified Audebert’s clinical severity grading (max. grade is 3) and the decision to use two vials of Viperfay™ was taken [4]. This promptly reduced local extension, improved systemic symptoms and laboratory results (e.g., thrombocytopenia). The improvement was consistent with the reported effectiveness of Viperfay™ in the treatment of V. berus and V. aspis-envenomed patients [6]. However, the recent prospective study concerning the use of Viperfay™ for V. aspis and V. berus envenomation showed that all clinical symptoms and pathological laboratory results disappeared within 24 h after treatment with a single dose of Viperfay™, with no recurrence of clinical or laboratory abnormalities [6]. These results corroborated earlier data that repeat administration did not produce any additional benefit to the clinical course in terms of the persistent functional impairment, incidence of haematoma or hospital length of stay [3,4]. On contrary, in the patient bitten by V. a. ammodytes pronounced thrombocytopenia reccurred 24 h after the incident despite timely treatment with the recommended dose of Viperfay™ and initial improvement in the clinical picture. Accordingly, it seems that the recommended protocol of polyvalent Viperfay™ for V. aspis and V. berus may be inadequate for the efficient treatment of V. ammodytes bites.

In order to address issues concerning its clinical effectiveness, pharmacokinetics on Viperfay™’s immunoglobulin F(ab’)₂ fragments was performed. It was shown that in V. a. ammodytes bitten patient, Viperfay™ systemic clearance was 1.64 (mL·h⁻¹)·kg⁻¹ with distribution and elimination half-lives of 7 h and 4 days respectively (Table 1). A relative comparison of this result and its interpretation in the light of other studies carried out on the pharmacokinetics of antivenoms in envenomed human, especially those based on F(ab’)₂ fragments as active principle [8–10], revealed that the pharmacokinetic properties of Viperfay™ were consistent with those obtained for GPO antivenom (Thai Government Pharmaceutical Organisation), pepsin-digested anti-Calloselasma rhodostoma serum, with the exception of distribution half-lives [9]. The discrepancy probably resulted from infrequent blood sampling in the
initial period following the administration of Viperfav™ and consequent omission of the rapid first phase, which might lead to a falsely longer distribution half-life. In comparison to other antivenoms that have been pharmacokinetically characterised using whole immunoglobulin G molecules or fabotherapics, the values with respect to Viperfav™’s elimination half-life and systemic clearance are among the highest obtained [8–14]. Nevertheless, it seems that in this patient an exhaustion of the available F(ab’)2 fragments occurring before all the relevant venom components were disabled was the likely cause of the recurrent thrombocytopenia after the V. a. ammodytes bite, since decrease of the serum F(ab’)2 fragments concentration and platelet count correlated remarkably well. This implies that the second drop in platelets was caused by the reappearance of free components of V. a. ammodytes venom during the clearance of F(ab’)2 fragments. These components of V. a. ammodytes venom might be sufficient for haemostatic disturbances to recur because of their potent toxicity. Accordingly, a repeated dose of Viperfav™ in V. a. ammodytes envenomed patients should now be evaluated during the delayed phase of thrombocytopenia (despite the fact that Viperfav™’s elimination half-life and systemic clearance are amongst the highest). Rebound of venom antigenemia and an association with recurrent thrombocytopenia is yet to be examined, since in this case V. a. ammodytes venom detected during recurrent thrombocytopenia was most likely incorporated into soluble immune complexes with F(ab’)2 fragments.

In light of the recurrent phenomena demonstrated by the case we report here, it might be necessary for V. a. ammodytes envenomations to be treated with an additional dose(s) of Viperfav™. Higher doses of Viperfav™ could be associated with a higher risk of side effects, even though single dose treatment has been shown to be safe and without adverse reaction [6]. Interestingly in this patient, sinus bradycardia after V. a. ammodytes bite was aggravated and coupled with a junctional escape rhythm during the infusion of the second Viperfav™ vial, resolving only at the end of the infusion. Arrhythmias in V. a. ammodytes bitten patients could be also due to the V. a. ammodytes venom itself, particularly the ammodytoxins. These are capable of inducing several conduction and electrophysiological disturbances, including the occurrence of malignant ventricular arrhythmias [15], due to direct myo-cytotoxic, electrophysiological, prothrombotic and coronary vasoconstrictive effects [16,17].

4. Conclusions

The recommended single dose of polyvalent Viperfav™ for V. aspis and V. berus envenomations may be inadequate for snakebites by V. a. ammodytes. A second dose of Viperfav™ might be necessary despite its 97 h elimination half-life. Higher doses of Viperfav™ may be associated with a greater risk of arrhythmia or other adverse events. Closely monitoring patients during Viperfav™ infusion is absolutely prerequisite.

5. Materials and Methods

5.1. Quantification of V. a. ammodytes Venom in Sera Samples

Determination of V. a. ammodytes venom in sera samples was performed as follows. Microtiter plate was coated with in-house rabbit anti-V. a. ammodytes venom IgG (1 µg·mL−1) in 0.05 M carbonate buffer, pH 9.6 (100 µL/well) and left overnight at room temperature. After washing and blocking with 2% (w/v) BSA in PBS/T (0.05% (w/v) Tween 20 in PBS) buffer (200 µL/well) for 2 h at 37 °C, the investigated sera (2- or 4-fold diluted) were added in duplicates and incubated overnight at room temperature (RT). The whole venom solution (100 ng·mL−1) used as standard was prepared from pool of sera from healthy donors (25% or 50%, v/v) and added in eight serial 2-fold dilutions in duplicates (100 µL/well). The plate was extensively washed and incubated with in-house equine anti-V. a. ammodytes venom IgG (100 µL/well of 5.7 µg·mL−1) and then with horseradish peroxidase (HRP)-anti-equine IgG (100 µL/well of 4000-fold dilution). Incubation was performed for 2 h at 37 °C. Finally, after washing o-phenylenediamine (OPD) solution (5.5 mM in 0.15 M citrate-phosphate buffer, pH 5.0) with 30% H2O2 (0.5 µL/mL of OPD solution) was added and incubated for half an hour at RT
in the dark. The enzymatic reaction was stopped with 12.5% H$_2$SO$_4$ (50 µL/well) and absorbance at 492 nm was measured.

5.2. Quantification of F(ab')$_2$ Fragments in Sera Samples

Sandwich enzyme-linked immunosorbent assay (ELISA) was developed as follows. Microtiter plate was coated with in-house rabbit anti-equine F(ab')$_2$ IgG (1 µg·mL$^{-1}$) in 0.05 M carbonate buffer, pH 9.6 (100 µL/well) and left overnight at room temperature. After washing and blocking with 2% (w/v) BSA in PBS/T (0.05% (w/v) Tween 20 in PBS) buffer (200 µL/well) for 2 h at 37 °C, the investigated sera were added in a few different, as first determined, suitable dilutions in duplicates (100 µL/well). Viperfav™ (100 ng·mL$^{-1}$) used as standard, was added in eight serial 2-fold dilutions (100 µL/well), also in duplicates. Incubation was performed overnight at RT. The plate was extensively washed and incubated with HRP-anti-equine IgG (100 µL/well of 5000-fold dilution) for 2 h at 37 °C. Finally, after washing OPD solution (5.5 mM in 0.15 M citrate-phosphate buffer, pH 5.0) with 30% H$_2$O$_2$ (0.5 µL/mL of OPD solution) was added and incubated for half an hour at RT in the dark. The enzymatic reaction was stopped with 1 M H$_2$SO$_4$ (50 µL/well) and absorbance at 492 nm was measured. Quantitative determination of F(ab')$_2$ content was done by multiplying each concentration obtained from the standard curve by the corresponding dilution factor. The assay was performed independently five times and the results are given as mean ± 95% confidence interval (CI).

5.3. Pharmacokinetic Analysis

Pharmacokinetic analysis of the measured concentrations was performed using PKSolver add-in software (version 2.0, China Pharmaceutical University, Nanjing, China) for Microsoft Excel [18]. Concentration-time data was fitted either to one-, two- or three-compartment model. Akaike information criterion (AIC) and Schwarz criteria (SC) were used for comparison of goodness of their fit [19].

Acknowledgments: The work was financially supported by University of Zagreb grant BM044 (to BH), Croatian Research Agency grant IP-2014-09-4915 (to BH), Slovenian Research Agency grant P1-0207 (to IK) and a bilateral cooperation grant Croatia-Slovenia BI-HR/16-17-002 (to BH and IK). The authors thank Marija Brgles, PhD, from University of Zagreb, Centre for Research and Knowledge Transfer in Biotechnology, for her irreplaceable technical expertise.

Author Contributions: T.K., B.H., I.K. and M.B. conceived and designed the experiments; M.B. and D.G. treated the patient; T.K., M.L.B. and B.H. performed the experiments; T.K. and M.B. analyzed the data; I.K. and B.H. contributed reagents/materials/analysis tools; T.K. and M.B. wrote the paper.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Chippaux, J.P. Epidemiology of snakebites in Europe: A systematic review of the literature. Toxicon 2012, 59, 1–14. [CrossRef] [PubMed]
2. Harry, P.; de Haro, L.; Asfar, P.; David, J.M. Evaluation de l’immunotherapie anti-viperine par fragments F(ab')$_2$ purifies (Viperfav™). Presse Med. 1999, 28, 1929–1934. [PubMed]
3. De Haro, L.; Glaiyal, M.; Tichadou, L.; Blanc-Brisset, I.; Hayek-Lanthois, M. Asp Viper (Vipera aspis) envenomation: Experience of the Marseille Poison Centre from 1996 to 2008. Toxins 2009, 1, 100–112. [CrossRef] [PubMed]
4. Boels, D.; Hamel, J.F.; Deguigne, M.B.; Harry, P. European viper envenomings: Assessment of Viperfav™ and other symptomatic treatments. Clin. Toxicol. 2012, 50, 189–196. [CrossRef] [PubMed]
5. De Haro, L. Management of snakebites in France. Toxicon 2012, 60, 712–718. [CrossRef] [PubMed]
6. Jollivet, V.; Hamel, J.F.; de Haro, L.; Labadie, M.; Sapori, J.M.; Cordier, L.; Villa, A.; Nisse, P.; Puskarczyk, E.; Berthelon, L.; et al. European viper envenomation recorded by French poison control centers: A clinical assessment and management study. Toxicon 2015, 108, 97–103. [CrossRef] [PubMed]
7. Claudet, I.; Grouteau, E.; Cordier, L.; Franchitto, N.; Bréhin, C. Hyperglycemia is a risk factor for high-grade envenomations after European viper bites (Vipera spp.) in children. *Clin. Toxicol. (Phila)* 2016, 54, 34–39. [CrossRef] [PubMed]

8. Thein-Than; Kyi-Thein; Mg-Mg-Thwin. Plasma clearance time of Russell’s viper (*Vipera russelli*) antivenom in human snake bite victims. *Trans. R. Soc. Trop. Med. Hyg.* 1985, 79, 262–263. [CrossRef]

9. Ho, M.; Silamut, K.; White, N.J.; Karbwang, J.; Looareesuwan, S.; Phillips, R.E.; Warrell, D.A. Pharmacokinetics of three commercial antivenoms in patients envenomed by the Malayan pit viper, *Calloselasma rhodostoma*, in Thailand. *Am. J. Trop. Med. Hyg.* 1990, 42, 260–266. [PubMed]

10. Meyer, W.P.; Habib, A.G.; Onayade, A.A.; Yakubu, A.; Smith, D.C.; Nasidi, A.; Daudu, I.J.; Warrell, D.A.; Theakston, R.D. First clinical experiences with a new ovine Fab *Echis ocellatus* snake bite antivenom in Nigeria: Randomized comparative trial with Institute Pasteur Serum (Ipser) Africa antivenom. *Am. J. Trop. Med. Hyg.* 1997, 56, 291–300. [PubMed]

11. Nielsen, H.; Sørensen, H.; Faber, V.; Svehag, S.E. Circulating immune complexes, complement activation kinetics and serum sickness following treatment with heterologous anti-snake venom globulin. *Scand. J. Immunol.* 1978, 7, 25–33. [CrossRef] [PubMed]

12. Ariaratnam, C.A.; Meyer, W.P.; Perera, G.; Eddelston, M.; Kuleratne, A.M.; Attagattu, W.; Sherife, R.; Richards, A.M.; Theakston, R.D.G.; Warrell, D.A. A new monospecific ovine Fab fragment antivenom for treatment of envenoming by the Sri Lankan Russell’s viper (*Daboia russelli russelli*): A preliminary dose-finding and pharmacokinetic study. *Am. J. Trop. Med. Hyg.* 1999, 61, 259–265. [PubMed]

13. Seifert, S.A.; Boyer, L.V. Recurrence Phenomena after Immunoglobulin Therapy for Snake Envenomations: Part 1. Pharmacokinetics and Pharmacodynamics of Immunoglobulin Antivenoms and Related Antibodies. *Ann. Emerg. Med.* 2001, 37, 189–195. [CrossRef] [PubMed]

14. Isbister, G.K.; Maduwage, K.; Saia, A.; Buckley, N.A.; Jayamanne, S.F.; Seyed, S.; Mohamed, F.; Chathuranga, U.; Mendes, A.; Abeyesinghe, C.; et al. Population pharmacokinetics of an Indian F(ab')2 snake antivenom in patients with Russell’s viper (*Daboia russelii*) bites. *PLoS Negl. Trop. Dis.* 2015, 9. [CrossRef] [PubMed]

15. Luksic, B.; Culic, V.; Stricevic, L.; Brizic, I.; Poljak, N.K.; Tadic, Z. Infant death after nose-horned viper (*Vipera ammodytes ammodytes*) bite in Croatia: A case report. *Toxicon* 2010, 56, 1506–1509. [CrossRef] [PubMed]

16. Saadeh, A.M. Case report: Acute myocardial infarction complicating a viper bite. *Am. J. Trop. Med.* 2001, 64, 280–282.

17. Frangides, C.Y.; Koulouras, V.; Kouni, S.N.; Tzortzatos, G.V.; Nikolaou, A.; Pneumaticos, J.; Pierrakeas, C.; Niarchos, C.; Kounis, N.G.; Koutsospanias, C.M. Snake venom poisoning in Greece. Experiences with 147 cases. *Eur. J. Intern. Med.* 2006, 17, 24–27. [CrossRef] [PubMed]

18. Zhang, Y.; Huo, M.; Zhou, J.; Xie, S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. *Comput. Methods Programs Biomed.* 2010, 99, 306–314. [CrossRef] [PubMed]

19. Ludden, T.M.; Beal, S.L.; Sheiner, L.B. Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. *J. Pharmacokinet. Biopharm.* 1994, 22, 431–445. [CrossRef] [PubMed]

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).